We detect cancer early by identifying key dynamic differences between cancer and healthy cells.
The Bluestar Genomics approach to detecting cancer early is anchored in epigenomics. Epigenomics is the process of tracking dynamic changes in cells in the body. Bluestar Genomics uniquely measures levels of the biomarker 5-hydroxymethylcytosine (5hmC) in a person’s blood to detect cancer using a novel analytical method.
Our Hydroxy-methylation Cytosine Analysis: Novel Epigenomics Approach to Measure Cancer Presence and Detect the Organ in which the Cancer Resides
Our unique epigenomics approach provides unprecedented precision in cancer detection by directly measuring the dynamic biological events in cells through genome analysis.